Skip to Content
MilliporeSigma
Search Within

05-321MG

Applied Filters:
Keyword:'05-321MG'
Showing 1-6 of 6 results for "05-321MG" within Papers
Hoang Thanh Chi et al.
Biomedical reports, 19(1), 47-47 (2023-06-29)
ETS variant transcription factor 6 (ETV6)-neurotrophic receptor tyrosine kinase 3 (NTRK3) (EN) fusions are typically found in rare diseases, such as primary renal fibrosarcoma (only six cases have been reported), secretory carcinoma of the breast and salivary gland (1 case)
Shaobo Wang et al.
The Journal of neuroscience : the official journal of the Society for Neuroscience, 38(1), 137-148 (2017-11-16)
Reelin controls neuronal migration and layer formation. Previous studies in reeler mice deficient in Reelin focused on the result of the developmental process in fixed tissue sections. It has remained unclear whether Reelin affects the migratory process, migration directionality, or
Xin A Zhang et al.
The Journal of biological chemistry, 278(29), 27319-27328 (2003-05-10)
KAI1/CD82 protein is a member of the tetraspanin superfamily and has been rediscovered as a cancer metastasis suppressor. The mechanism of KAI1/CD82-mediated suppression of cancer metastasis remains to be established. In this study, we found that migration of the metastatic
Hui Guo et al.
Acta pharmacologica Sinica, 39(3), 425-437 (2017-11-10)
STAT1 and STAT3 are two important members of the STAT (signal transducers and activators of transcription) protein family and play opposing roles in regulating cancer cell growth. Suppressing STAT3 and/or enhancing STAT1 signaling are considered to be attractive anticancer strategies.
Zhi Liu et al.
The Journal of biological chemistry, 290(12), 7535-7562 (2015-01-15)
Producing pure and well behaved bispecific antibodies (bsAbs) on a large scale for preclinical and clinical testing is a challenging task. Here, we describe a new strategy for making monovalent bispecific heterodimeric IgG antibodies in mammalian cells. We applied an
Yongsheng Ruan et al.
Experimental and therapeutic medicine, 23(1), 47-47 (2021-12-23)
Treatment of resistant or recurrent acute lymphoblastic leukemia (ALL) remains a challenge. It was previously demonstrated that the adhesion molecule integrin α4, referred to hereafter as α4, mediates the cell adhesion-mediated drug resistance (CAM-DR) of B-cell ALL by binding to
Page 1 of 1